Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (291-300 of 516) with videos related to

Pageof 52
Sort By:
Kidney International Reports|May 2, 2022
Kidney Transplant Outcomes of Patients With Multiple MyelomaCihan Heybeli, Andrew J Bentall, Mariam Priya Alexander, et al.
Leukemia|September 30, 2018
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosisJithma P Abeykoon, Saurabh Zanwar, Angela Dispenzieri, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Blood Cancer Journal|September 23, 2021
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Saurabh Zanwar, Prashant Kapoor, et al.
Blood Advances|December 5, 2024
Prognostic impact of patient-reported symptoms in multiple myelomaNadine Abdallah, Arwa Bohra, Aytaj Mammadzadeh, et al.
British Journal of Haematology|November 19, 2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemiaAneel Paulus, Kasyapa Chitta, Sharoon Akhtar, et al.
Blood Cancer Journal|June 18, 2025
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working GroupXinyan Lu, Erica F Andersen, Rahul Banerjee, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Pageof 52

Showing results (291-300 of 516) with videos related to

Sort By:
Pageof 52
Kidney International Reports|May 2, 2022
Kidney Transplant Outcomes of Patients With Multiple MyelomaCihan Heybeli, Andrew J Bentall, Mariam Priya Alexander, et al.
Leukemia|September 30, 2018
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosisJithma P Abeykoon, Saurabh Zanwar, Angela Dispenzieri, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Blood Cancer Journal|September 23, 2021
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Saurabh Zanwar, Prashant Kapoor, et al.
Blood Advances|December 5, 2024
Prognostic impact of patient-reported symptoms in multiple myelomaNadine Abdallah, Arwa Bohra, Aytaj Mammadzadeh, et al.
British Journal of Haematology|November 19, 2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemiaAneel Paulus, Kasyapa Chitta, Sharoon Akhtar, et al.
Blood Cancer Journal|June 18, 2025
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working GroupXinyan Lu, Erica F Andersen, Rahul Banerjee, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Pageof 52